NCT02711202 2026-04-13
Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation
Institute for Clinical and Experimental Medicine
Phase NA Completed
Clinical Trials
9 trialsNCT02565901 2021-10-01
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
University of Washington
Phase 1/2 Terminated
NCT01083368 2019-08-21
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT01026623 2019-06-17
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00311623 2019-02-22
Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00378703 2018-11-14
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01938573 2017-10-20
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
University of Washington
Phase 1/2 Completed
NCT00923845 2017-09-29
Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00353301 2014-04-14
Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma
University of Colorado, Denver
Phase 2 Completed